CARLSBAD, Calif., Sept. 12, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host an investor and analyst day on Wednesday, October 4. The event will take place at the Westin New York Grand Central from 8:00 a.m. to 3:00 p.m. Eastern Time and will also be webcast. The agenda will include presentations by members of the Ionis management team and the following notable key opinion leaders:
Please click here to register for the event. Webcast participants may submit questions via email at This email address is being protected from spambots. You need JavaScript enabled to view it.. Questions must be received by October 2 to be addressed during the live event. A webcast replay will be available within 48 hours after the event at https://ir.ionispharma.com/events-and-presentations/upcoming-events.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.

| Last Trade: | US$81.80 |
| Daily Change: | 2.23 2.80 |
| Daily Volume: | 1,002,732 |
| Market Cap: | US$13.250B |
December 02, 2025 December 01, 2025 November 14, 2025 November 12, 2025 | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load